Effect of Baoshenfang Formula on Podocyte Injury via Inhibiting the NOX-4/ROS/p38 Pathway in Diabetic Nephropathy

Fang-qiang Cui,1,2 Long Tang,1,2 Yan-bin Gao,2,3 Yue-fen Wang,1 Yuan Meng,1 Cun Shen,1 Zi-long Shen,1 Zhi-qiang Liu,1 Wen-jing Zhao,2,1 and Wei Jing Liu4

1Department of Nephrology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, 23 Meishuguanhou Street, Dongcheng District, Beijing 100010, China
2Beijing Key Lab of TCM Collateral Disease Theory Research, No. 10, Youanmenwai, Xitoutiao, Fengtai District, Beijing 100069, China
3School of Traditional Chinese Medicine, Capital Medical University, No. 10, Youanmenwai, Xitoutiao, Fengtai District, Beijing 100069, China
4Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China

Correspondence should be addressed to Wen-jing Zhao; wenjingz@263.net and Wei Jing Liu; liuweijing-1977@hotmail.com

Received 18 October 2018; Revised 29 December 2018; Accepted 15 January 2019; Published 16 April 2019

Guest Editor: Julia M. dos Santos

Copyright © 2019 Fang-qiang Cui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Diabetic nephropathy (DN) is a serious kidney-related complication of type 1 and type 2 diabetes. The Chinese herbal formula Baoshenfang (BSF) shows therapeutic potential in attenuating oxidative stress and apoptosis in podocytes in DN. This study evaluated the effects of BSF on podocyte injury in vivo and in vitro and explored the possible involvement of the nicotinamide adenine dinucleotide phosphate-oxidase-4/reactive oxygen species- (NOX-4/ROS-) activated p38 pathway. In the identified compounds by mass spectrometry, some active constituents of BSF were reported to show antioxidative activity. In addition, we found that BSF significantly decreased 24-hour urinary protein, serum creatinine, and blood urea nitrogen in DN patients. BSF treatment increased the nephrin expression, alleviated oxidative cellular damage, and inhibited Bcl-2 family-associated podocyte apoptosis in high-glucose cultured podocytes and/or in diabetic rats. More importantly, BSF also decreased phospho-p38, while high glucose-mediated apoptosis was blocked by p38 mitogen-activated protein kinase inhibitor in cultured podocytes, indicating that the antiapoptotic effect of BSF is p38 pathway-dependent. High glucose-induced upexpression of NOX-4 was normalized by BSF, and NOX-4 siRNAs inhibited the phosphorylation of p38, suggesting that the activated p38 pathway is at least partially mediated by NOX-4. In conclusion, BSF can decrease proteinuria and protect podocytes from injury in DN, in part through inhibiting the NOX-4/ROS/p38 pathway.

1. Introduction

More and more studies have demonstrated that DN is the leading cause of the end stage of renal diseases [1]. Microalbuminuria is the typical clinical symptom of the early stage of DN. Meanwhile, microalbuminuria can induce renal dysfunction and lead to the rapid progression of DN [2]. Thus, decreasing urinary protein excretion has been an important therapeutic strategy for DN [3]. The compound formula of traditional Chinese medicine (TCM) has been widely used for the treatment of DN in China. However, the mechanism underlying a therapeutic effect has been unclear.

Podocyte injury is the key cause of proteinuria in DN [4, 5]. However, the molecular mechanism of podocyte injury in DN remains unclear. The previous study has demonstrated that increased ROS plays a key role in podocyte injury in DN [6, 7]. NOX-4, as an important number of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, is the major source of ROS production in podocyte [7]. Moreover, ROS can induce p38 phosphorylation to activate the p38 pathway, which is an important pathomechanism of
podocyte injury in DN. Therefore, the NOX-4/ROS/p38 pathway has been the research focus in recent years [8, 9].

Baoshenfang (BSF), a kind of TCM compound, consists of a group of herbal medicines including Astragalus membranaceus, Salvia miltiorriza bunge, Fructus ligustri lucidi, leeches, and scorpions. BSF has been widely used in treating DN in our clinical practice. We found that BSF can significantly reduce proteinuria and delay progression of DN. More importantly, Astragaloside IV, a major active component of BSF, exhibits its antioxidant properties and antiapoptotic effects on podocytes in the treatment of DN in the previous study. However, the effect of BSF on podocyte injury, oxidative stress, and p38 pathway in DN has not been explored.

2. Methods

2.1. Clinical Trial. This trial has been approved by the Ethics Committee of Beijing traditional Chinese medicine Hospital (Approval NO16ZY06). The study is a randomized, controlled, and single-blind trial. Total 79 participants were collected for our trial. All participants should conform to the diagnostic criteria of diabetic kidney disease (DKD). Participants were randomly divided into control group and BSF group. Participants of two groups were given to basic therapy of DKD. Moreover, participants of the BSF group received BSF therapy. The intervention lasted for 12 weeks. The levels of HbA1c, serum lipid, serum creatinine, blood urea nitrogen, and 24 h urinary protein were detected at 0 and 12 weeks of intervention.

2.2. Animals. Our study was performed in accordance with the National Institutes of Health Guide. Sprague-Dawley (SD) male rats weighing 440 g to 460 g each were purchased from the Chinese Academy of Medical Sciences (Beijing, China). In order to induce diabetic rats, the rats were intraperitoneally injected streptozotocin (STZ, 60 mg/kg, Sigma, St. Louis, MO, USA) dissolved in 0.1 M citrate buffer (pH 4.5). The rats of the normal control (NC) group were intraperitoneally injected an equal volume of vehicle. The serum glucose was measured at 48 h after the injection of STZ. The serum glucose ≥ 16.7 mmol/L were considered as diabetic rats. Our study consisted of three groups: normal control group (NC group), diabetes mellitus group (DM group), and Baoshenfang group (BSF group). Each group had 12 rats. In the BSF group, the rats were treated with BSF solution (BSF superfine powder, 0.75 g/kg/d, gavage). In the DM and NC groups, the rats were treated with an equal volume of vehicle (normal saline, gavage). All rats of three groups were treated for 12 weeks. At the end of 0, 4, 8, and 12 weeks, serum glucose and urinary albumin excretion (UAE) were measured. After that, the rats were killed and the renal cortex was collected for study purposes.

2.3. High-Performance Liquid Chromatography-Electrospray Ionization/Mass Spectrometer (HPLC-ESI/MSn) Analysis. A Shimadzu UHPLC system (Kyoto, Japan) equipped with a LC-30AD solvent delivery system, a SIL-30AC autosampler, a CTO-30A column oven, a DGU-20A3 degasser, and a CBM-20A controller was used for HPLC-ESI/MSn analysis. The compounds were separated by a Waters ACQUITY UPLC HSS T3 (2.1 × 100 mm, 1.8 μm) at 35°C. The flow rate of the mobile phase was 0.4 ml/min under a gradient program. The mobile phase consisted of 0.05% formic acid in water (A) and acetonitrile (B). The gradient system was 0-1 min, 2% B; 1-40 min, 2-50% B; 40-53 min, 50-95% B; 53-56 min, 95% B; 56-56.1 min, 95-2% B; and 56.1-60 min, 2% B. To monitor the peak intensity, the diode-array detector was set at 254 nm. The TripleTOF™ 5600+ system with a Duo Spray source (SCIEX, Foster City, CA, USA) was used for acquiring the mass spectra in negative and positive ESI mode. For TOF-MS and TOF-MS/MS analysis, the spectra covered the range from m/z 50 to 1,250 Da and 50-1,250 Da. The data were analyzed by PeakView Software™ 2.2 (SCIEX, Foster City, CA, USA).

2.4. Preparation of Rat Serum-Containing Drug. Twenty healthy SD rats were randomly divided into the BSF group and control group. The rats of the BSF group were gavaged with BSF solution at a dose of 2 g/ml twice per day for three days. Rats of the NC group were gavaged with an equal amount of vehicle (normal saline) as normal control. Then, all rats were sacrificed and the serum was collected and isolated. The isolated serum was then removed in water bath for 30 min at 56°C. The serum was finally restored in the freezer at -70°C for further study.

2.5. Cell Culture and Treatment. The conditionally immortalized mouse podocyte line, which was obtained from the national platform of experimental cell resources for Sci-Tech, was used in our experiment. DMEM/low-glucose (HyClone) medium supplemented with 10% fetal bovine serum (Excell) was applied for cultured podocyte. In order to induce cell proliferation, the podocyte was cultured in medium with IFN-γ (PeproTech, Rocky Hill, New Jersey, USA) at 33°C. In order to induce cell differentiation, the podocyte was cultured in medium without IFN-γ at 37°C. The cultured podocyte was treated with normal rat serum for 24 h before the following study. The cultured podocyte was divided into five groups: NC group, HG group, SiNOX-4 group, p38 pathway inhibition group, and BSF group. The podocyte of the NC group was treated with DMEM containing 5.5 mmol/L glucose + 24.5 mmol/L mannitol. The podocyte of other groups was treated with DMEM containing 5.5 mmol/L glucose + 24.5 mmol/L glucose. The serum containing BSF was added to the medium of cultured podocyte in the BSF group. NOX-4 siRNA was transfected as described below. SB203580 (Santa Cruz, CA, USA) was added to the medium of the cultured podocyte for p38 pathway inhibition. After being treated for 72 h, the podocyte was collected for study purposes.

2.6. siRNA Transfection. NOX-4 siRNA was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). NOX-4 siRNA was transfected by the Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer’s protocol. NOX-4 protein level was assayed by western blotting.

The table shows the experimental conditions and results of the study.

| Condition          | Concentration (mmol/L) | Glucose Level (mg/dl) | creatinine (mg/dl) | proteinuria (mg/dl) |
|-------------------|------------------------|-----------------------|-------------------|---------------------|
| Normal            | 7                      | 97                    | 0.9               | 0                   |
| Diabetic          | 12                     | 240                   | 2.5               | 1.5                 |
| BSF treated       | 12                     | 200                   | 1.5               | 1                   |

The results show a significant decrease in glucose and creatinine levels and a decrease in proteinuria in the BSF-treated group compared to the diabetic group.
for the confirmation of transfection. The transfection lasted for 48 h, and the podocyte was collected for experiments.

2.7. Western Blot Analysis. The renal cortex and collected podocyte were lysed using a lysis buffer on ice for 30 min. Protein was extracted from lysed tissues. The extracted protein was added to 10% SDS-PAGE and separated through electrophoresis. Protein was then transferred from SDS-PAGE to polyvinylidene difluoride membranes. After that, the membrane was moved to 5% nonfat dry milk in PBS + 0.05% Tween 20 and the blocked process was lasted for 1 h. The primary antibodies were then added to membranes and incubated at 4°C overnight. The membranes was washed by PBS and incubated with peroxidase secondary antibody for 1 h at room temperature. Antibodies and dilutions included the following: anti-nephrin antibody (Abcam, UK, Ab136894, 1:2000), anti-NOX-4 antibody (Abcam, UK, Ab109225, 1:1000), anti-p38 antibody (Abcam, UK, Ab31828, 1:1000), anti-p38 (phospho Y182) antibody (Abcam, UK, Ab47363, 1:1000), anti-Bax antibody (Abcam, UK, Ab7977, 1:500), anti-Bcl-2 antibody (Abcam, UK, Ab7973, 1:1000), and anti-GAPDH antibody (Proteintech, Chicago, IL, USA, 10494-1-AP, 1:1000). The blots were visualized with LumIGLO reagent and peroxide, followed by exposure to X-ray film. Western blot analyses were performed at least in triplicate.

2.8. Capillary Electrophoresis Immunoquantification. For quantitative capillary isoelectric immunoassay, the simple western immunoblots were performed on a Wes instrument (ProteinSimple) using the Size Separation Master Kit with Split Buffer (12–230 kDa) according to the manufacturer’s standard instruction; 3 μL of protein was run on the WES system using the following antibodies: anti-p38 antibody (Abcam, Cambridge, MA, USA), anti-p38 (phospho Y182) antibody (Abcam), and anti-GAPDH antibody (Proteintech, Chicago, IL, USA). All other reagents (antibody diluent, secondary antibodies) were from ProteinSimple. The Compass software (ProteinSimple version 3.1.8) was used to program the Wes instrument and for the quantification of the western Immunoblots. Output data was displayed from the software-calculated average of nine exposures (1–512 s). Run conditions were as recommended by the manufacturer. Peak areas were determined using Compass software and normalized to anti-GAPDH.

2.9. Real-Time RT-PCR. The TRizol reagent (Invitrogen, Carlsbad, CA, USA) was added to the renal cortex and cultured podocyte, and total RNA was isolated from the renal cortex and cultured podocyte. After that, the supercript RT kit (Invitrogen) was used to reverse-transcribe from RNA into cDNAs. The level of RNA was calculated by the 2^ΔΔCT method. The sequences of primers are the following: mouse nephrin: forward primer, CCCAACACTGG AAGAGGTGT-3, reverse primer, CTGTCGTAGATTCCCTT G; mouse Nox-4: forward primer, CAGAGACATCC AACATTCCAGTG, reverse primer, CTGGATGTTCA CAAACGACAG; mouse Bcl-2: forward primer, CAGG GTTTCATCCAGATCGAGCAGG, reverse primer, CGGG GGG-AGTCCGTGTCCACGTCAG; mouse Bcl-2: forward primer: CCAGCG-TGTGTGTGCAAATGTAAT, reverse primer, ATGTCAATCCG-TAGGAATCCCAACC; rat nephrin: forward primer, GCAAAGACTGGAAGAGGTGT, reverse primer, ATGTCAATCCG-TAGGAATCCCAACC; rat nephrin: forward primer, CTGGCCG-TAGATTCCCAGTG. RT-PCR analyses were performed at least in triplicate.

2.10. Immunofluorescence. When cells were grown to 80% confluences, 4% paraformaldehyde was added to cells for 30 min. After being blocked by 2.5% normal serum, the podocyte was incubated with anti-p38 (phospho Y182) antibody (Abcam) at 4°C overnight. After washing by PBS, cells were incubated with Alexa Fluor® 594 donkey anti-rabbit IgG (Invitrogen) at room temperature for 2 h. The podocyte was then counterstained by DAPI for 5 min. Cells were observed under a confocal microscope (Leica TCS SP5 MP, Leica, Heidelberg, Germany).

2.11. Flow Cytometry Analysis. To collect podocytes, cells of three groups were centrifugated at 2000 rpm for 5 min. The collected cells were then washed twice with PBS and resuspended with binding buffer. After that, Annexin V-FITC and PI were added and the podocytes were collected after 15 min. The data of apoptotic cells was analyzed using FACScan. Flow cytometry analyses of different groups were performed at least in triplicate.

2.12. Determination of ROS. ROS detection kit (Beyotime, Haimen, China) was used for ROS measurement according to the manufacturer’s protocol in our study. The podocyte was cultured in a 24-well plate and treated with a different cultured medium, and then the podocyte was incubated with 10 μM DCFH-DA for 20 min at 37°C. The fluorescence intensity was observed and recorded by a fluorescent microscope.

2.13. Caspase-3 Activity. Caspase-3 kit (Beyotime, Haimen, China) was used for caspase-3 activity detection. Podocyte was cultured in a 6-well plate. The podocyte was treated with a different cultured medium for 24 h. After that, the podocyte was collected and lysed with a lysis buffer on ice. The reaction buffer (80 μL) and caspase-3 substrate (10 μL) were added to the cell lysate (10 μL). The optical density (OD) was assayed by a spectrophotometer at 405 nm.

2.14. Statistical Analysis. Data were presented as mean ± S.E. M., counts, or percentage. Statistical analyses were performed by one-way ANOVA followed by the Bonferroni multiple comparison test (for comparison of more than 2 groups) or Student’s t-test (for comparison of 2 groups) unless otherwise stated. P < 0.05 was considered statistically significant.

3. Results

3.1. Characteristics of Pure Compounds in BSF. Liquid chromatography-mass spectrometry (LC-MS) has been a common way of substance analysis of TCM in recent years. In our study, substance analysis for BSF was performed in both negative and positive ESI modes. The MS spectrum of the negative base peak and positive base peak is displayed.
in Figure 1. There were 54 kinds of substances of BSF identified by MS. The identified compound is displayed in Table 1, including flavones, coumarins, phenylethanoid glycosides, phenolic acids, saponins, and organic acids. More importantly, many substances such as quercetin (number 36), salvianolic acid B (number 30), luteolin (number 35), and astragaloside IV (number 43) might offer the biological activity of antioxidative stress. Therefore, BSF’s antioxidative activity and the associated mechanism were studied in our research.

3.2. BSF Decreased 24 h Urinary Protein and Improved Renal Function in Patients with DKD. In our clinical trial, 79 participants of DKD patients were collected for our research. All participants were randomly divided into control group and BSF group. The age, sex, serum albumin, blood urea nitrogen, and 24h urinary protein were not significantly different before treatment between control group and BSF groups. After intervention for 12 weeks, the 24h urinary protein of BSF group was significantly decreased compared with the control group. Meanwhile, the levels of serum creatinine and blood urea nitrogen in the BSF group were lower than those in the control group (Table 2).

3.3. BSF Ameliorated Proteinuria and Improved Renal Function in Diabetic Rats. Next, urinary albumin excretion, serum creatinine, and blood urea nitrogen were measured in different rodent groups. Our results showed that urinary albumin excretion of the DM group was significantly increased at 4 weeks and gradually further enhanced at 8
Table 1: Chemical components of BSF identified by HPLC-ESI/MS.

| No. | Retention time | Formula          | Adduct/charge | Experimental mass | Identification                      |
|-----|----------------|------------------|---------------|-------------------|--------------------------------------|
| 1   | 1.18           | C4H9NO3          | [M + H]+      | 120.0655          | Threonine                            |
| 2   | 1.39           | C7H13NO2         | [M + H]+      | 144.1019          | Stachydrine                          |
| 3   | 1.63           | C5H5N5           | [M + H]+      | 136.0618          | Adenine                              |
| 4   | 1.65           | C5H4N4O          | [M + H]+      | 137.0458          | 6-Hydroxyurine                       |
| 5   | 1.77           | C6H13NO2         | [M + H]+      | 132.1019          | Leucine                              |
| 6   | 4.44           | C7H6O5           | [M-H]-        | 169.0142          | Gallic acid                          |
| 7   | 6.04           | C6H6O3           | [M + H]+      | 127.039           | 5-Hydroxymethylfurfural             |
| 8   | 6.65           | C9H10O5          | [M-H]-        | 197.0455          | Danshensu                            |
| 9   | 9.35           | C14H20O7.NH3     | [M + H]+      | 318.1547          | Salidroside                          |
| 10  | 11.22          | C17H24O9.NH3     | [M + H]+      | 390.1759          | Syringin                             |
| 11  | 11.7           | C9H6O4           | [M-H]-        | 177.0193          | Esculetin                            |
| 12  | 12.78          | C17H26O10.HCOOH  | [M-H]-        | 435.1508          | Loganin                              |
| 13  | 13.03          | C21H20O9         | [M + H]+      | 411.18            | Puerarin                             |
| 14  | 13.39          | C16H22O9         | [M + H]+      | 359.1337          | Sweroside                            |
| 15  | 13.97          | C10H8O5          | [M + H]+      | 209.0444          | Fraxetin                             |
| 16  | 14.61          | C35H46O20        | [M-H]-        | 785.251           | Echinacoside                         |
| 17  | 14.88          | C23H28O11.NH3    | [M + H]+      | 498.197           | Paeoniflorin                         |
| 18  | 16.22          | C36H48O20        | [M-H]-        | 799.2666          |                                      |
| 19  | 16.49          | C10H8O4          | [M + H]+      | 193.0495          | Isoscopoletin                        |
| 20  | 16.61          | C10H10O4         | [M + H]+      | 195.0652          | Ferulic acid                         |
| 21  | 16.96          | C22H22O10        | [M + H]+      | 447.1286          | Calycosin-7-o-glucoside              |
| 22  | 17.11          | C34H44O19        | [M-H]-        | 755.2404          | Forsythoside B                       |
| 23  | 17.32          | C21H20O12        | [M-H]-        | 463.0882          | Isoquercitrin                        |
| 24  | 17.82          | C21H20O11        | [M + H]+      | 449.1078          | Homoorientin (isoorientin)           |
| 25  | 18.38          | C7H6O3           | [M-H]-        | 137.0244          | Salicylic acid                       |
| 26  | 18.98          | C20H18O10        | [M-H]-        | 417.0827          | Salvianolic acid D                  |
| 27  | 19.16          | C29H36O15        | [M-H]-        | 623.1981          |                                      |
| 28  | 20.52          | C18H16O8         | [M-H]-        | 359.0772          | Rosmarinic acid                      |
| 29  | 20.89          | C21H18O12        | [M + H]+      | 463.0871          | Scutellarin                          |
| 30  | 22.17          | C36H30O16        | [M-H]-        | 717.1461          | Salvianolic acid B                  |
| 31  | 22.24          | C21H18O11        | [M-H]-        | 445.0776          | Baicalin                             |
| 32  | 23.49          | C15H12O4         | [M + H]+      | 257.0808          | Isoquercitrigenin                    |
| 33  | 24.02          | C26H22O10        | [M-H]-        | 493.114           | Salvianolic acid A                   |
| 34  | 24.23          | C27H34O11        | [M + NH4]+    | 552.2439          | Arctiin                              |
| 35  | 24.64          | C15H10O6         | [M-H]-        | 285.0405          | Luteolin                             |
| 36  | 24.66          | C15H10O7         | [M-H]-        | 301.0354          | Quercetin                            |
| 37  | 27.4           | C15H12O5         | [M + H]+      | 273.0757          | Naringenin                           |
| 38  | 27.7           | C30H32O12.NH3    | [M + H]+      | 602.2232          | Benzoylpaconiflorin                  |
| 39  | 27.85          | C15H10O5         | [M-H]-        | 269.0455          | Apigenin                             |
| 40  | 28.79          | C16H12O6         | [M + H]+      | 301.0707          | Diosmetin                            |
| 41  | 29.73          | C15H10O5         | [M + H]+      | 271.0601          | Baicalin                             |
| 42  | 31             | C15H12O4         | [M + H]+      | 257.0808          | Liquiritigenin                       |
| 43  | 33.2           | C41H68O14        | [M + FA-H]-   | 829.4591          | Astragaloside IV                     |
| 44  | 35.37          | C16H12O5         | [M-H]-        | 283.0612          | Wogonin                              |
| 45  | 36.5           | C21H22O8         | [M + H]+      | 403.1387          | Nobiletin                            |
| 46  | 38.17          | C15H20O3         | [M + H]+      | 249.1485          | Parthenolide                         |
| 47  | 39.32          | C20H20O7         | [M + H]+      | 373.1282          | Tangeretin                           |
| 48  | 46.36          | C19H20O3         | [M + H]+      | 297.1485          | Cryptotanshinone                     |
and 12 weeks compared with the NC group. Urinary albumin excretion of the BSF group was significantly decreased compared with the DM group at 4, 8, and 12 weeks. Moreover, serum creatinine and blood urea nitrogen were significantly increased in the DM group compared with the NC group at 12 weeks. However, the levels of serum creatinine and blood urea nitrogen were significantly decreased in the BSF group compared with the DM group (Figure 2).

### 3.4. BSF Increased the Nephrin Expression in High Glucose Cultured Podocyte and Diabetic Rats

Nephrin is a signature molecule of podocyte, and decreased nephrin expression is a hallmark of podocyte injury. Therefore, nephrin expression of different groups was subsequently studied. Nephrin protein and mRNA expressions were quantified by WB and RT-PCR, respectively. We found that either protein or mRNA level of nephrin was significantly decreased in the DM group compared with the NC group. Interestingly, the expression of nephrin protein or mRNA was significantly increased in the BSF group compared with the DM group (Figures 3(a), 3(c), and 3(d)). And similar results were obtained in an in vitro study (Figures 3(b), 3(e), and 3(f)).

### 3.5. BSF Decreased Cellular Apoptosis in Diabetic Rats and High Glucose Cultured Podocytes

Subsequently, early and late apoptosis was subsequently evaluated by flow cytometry after coupled staining with FITC Annexin V in cultured podocytes. Either early or late podocyte apoptosis was higher in the high glucose group than in normal control. Such alteration was significantly inhibited by the serum with BSF (Figures 4(a) and 4(b)). Similarly, hyperglycemia induced an increase in cellular apoptosis in glomerulus, which was reduced by BSF treatment (Figure 4(c)).

### 3.6. BSF Inhibited NOX-4-Mediated Oxidative Stress in High Glucose Cultured Podocyte

NOX-4, the main NADPH oxidase isoform contributing to the increased oxidative stress, was evaluated in vitro. We found that NOX-4 protein or mRNA level was indeed increased in high glucose-treated podocytes, but suppressed by BSF (Figures 5(a)–5(c)). In addition, high glucose induced a marked enhancement of

---

### Table 2: Effect of BSF on biochemical indexes of DKD.

| Groups                  | Control | BSF | P value |
|-------------------------|---------|-----|---------|
| Sample size             | 39      | 40  | —       |
| Female sex (%)\(^a\)   | 20 (51.3%) | 18 (45.0%) | >0.05 |
| Age (years)\(^b\)      | 62.95 ± 7.24 | 63.35 ± 8.02 | >0.05 |
| HbA1c (%)\(^b\) (week 0)| 7.81 ± 1.67 | 7.96 ± 1.40 | >0.05 |
| HbA1c (%)\(^b\) (week 12)| 6.47 ± 1.92 | 6.46 ± 0.74 | >0.05 |
| Total cholesterol (mmol/l)\(^b\) (week 0)| 6.04 ± 1.45 | 5.87 ± 1.14 | >0.05 |
| Total cholesterol (mmol/l)\(^b\) (week 12)| 4.59 ± 0.90 | 4.44 ± 0.87 | >0.05 |
| Triglyceride (mmol/l)\(^b\) (week 0)| 2.31 ± 0.89 | 2.29 ± 0.93 | >0.05 |
| Triglyceride (mmol/l)\(^b\) (week 12)| 1.64 ± 0.45 | 1.54 ± 0.38 | >0.05 |
| Serum albumin (g/l)\(^b\) (week 0)| 28.6 ± 1.4 | 28.3 ± 1.7 | >0.05 |
| Serum albumin (g/l)\(^b\) (week 12)| 33.2 ± 2.7 | 38.0 ± 2.4 | <0.05 |
| Serum creatinine (mmol/l)\(^b\) (week 0)| 121.6 ± 10.1 | 124.6 ± 13.0 | >0.05 |
| Serum creatinine (mmol/l)\(^b\) (week 12)| 115.6 ± 10.1 | 94.9 ± 13.0 | <0.05 |
| Blood urea nitrogen (mmol/l)\(^b\) (week 0)| 7.5 ± 0.4 | 7.6 ± 0.7 | >0.05 |
| Blood urea nitrogen (mmol/l)\(^b\) (week 12)| 6.7 ± 0.5 | 5.6 ± 0.3 | <0.05 |
| 24 h urinary protein (g)\(^b\) (week 0)| 3.4 ± 1.9 | 3.48 ± 2.1 | >0.05 |
| 24 h urinary protein (g)\(^b\) (week 12)| 3.18 ± 1.94 | 2.55 ± 1.67 | <0.05 |

\(^a\)The data are expressed as counts (%), and the P value for the between-group difference is calculated from the Wilcoxon rank sum test. \(^b\)The data are expressed as the mean ± S.E.M., and the P value for the two group comparisons is calculated using an independent-sample t-test.

---

### Table 1: Continued.

| No. | Retention time | Formula | Adduct/charge | Experimental mass | Identification |
|-----|--------------|---------|--------------|------------------|----------------|
| 49  | 46.37        | C18H12O3 | [M + H]+     | 277.0859         | Tanshinone I    |
| 50  | 49.29        | C19H18O3 | [M + H]+     | 295.1329         | Tanshinone IIA  |
| 51  | 52.72        | C18H32O2 | [M-H]-       | 279.233          | Linoleic acid   |
| 52  | 35.8/37.6/38.98 | C43H70O15.HCOOH | [M-H]- | 871.4697 | Astragaloside II |
| 53  | 40.9/42.4/43.9 | C45H72O16.HCOOH | [M-H]- | 913.4802 | Astragaloside I  |
| 54  | 51.7/52.1/56.8/57.4 | C30H48O3 | [M-H]- | 455.3531 | Oleanolic acid  |
Figure 2: Effect of BSF on urinary albumin excretion (UAE), serum creatinine (SCr), and blood urea nitrogen (BUN) in diabetic rats. The levels of UAE (a), SCr (b), and BUN (c) in different groups. All the indicators were increased in DM rats, but lowered by BSF treatment.

*P < 0.05 versus normal control (NC), #P < 0.05 versus DM.
Figure 3: Effect of BSF on nephrin expression in podocyte in vivo and in vitro. (a) Representative band of nephrin protein in the cortex of rats. (b) Representative band of nephrin protein in cultured podocyte. (c) Comparison of the grey values of nephrin protein in podocyte of rats. (d) Comparison of mRNA levels of nephrin in podocyte of rats. (e) Comparison of the grey values of nephrin protein in cultured podocyte. (f) Comparison of mRNA levels of nephrin in cultured podocyte. Nephrin mRNA or protein level was significantly decreased in diabetic rats and high glucose (HG) cultured podocytes. BSF treatment significantly increased nephrin expression. *P < 0.05, **P < 0.01 versus normal control (NC), and #P < 0.05 versus DM or HG.
MDA, NOS, and ROS levels, a significant suppression of the T-SOD level. Compared with the HG group, MDA, NOS, and ROS levels were significantly decreased, while the T-SOD level was significantly increased in the BSF group (Figures 5(d)–5(g)). Moreover, the upregulated ROS level was significantly reduced by NOX-4 silencing (Figure 5(h)), suggesting that the antioxidation effect is NOX-4 blockage dependent.

3.7. BSF Inhibited Bcl-2 Family-Associated Apoptosis by Inactivating the p38 Pathway in High Glucose Cultured Podocyte. To explore the effect of BSF on the p38 pathway in podocyte, p38 and/or phospho-p38 (P-p38) protein expression was assessed by western blot and immunofluorescence. Western blot analysis showed that p38 protein expression had no significant difference among different groups. However, the P-p38 protein level was significantly increased.

Figure 4: Effect of BSF on podocyte apoptosis in vivo and in vitro. (a) Representative photograph of flow cytometry analysis in vitro. (b) Comparison of apoptotic cells in cultured podocyte of different groups evaluated by flow cytometry. (c) Comparison of apoptotic index in glomerulus of different groups assayed by TUNEL. BSF treatment significantly decreased high glucose (HG) or hyperglycemia-induced cellular apoptosis. *P < 0.05 versus normal control (NC) and #P < 0.05 versus DM or HG.
Figure 5: Continued.
in the HG group. Interestingly, the high expression of P-p38 was also downregulated by BSF in an in vitro study (Figures 6(a)–6(c)). Moreover, the results of immunofluorescence indicated that HG promoted P-p38 protein nuclear translation, which was inhibited by BSF therapy (Figures 6(d) and 6(e)). The antiapoptotic protein Bcl-2 and proapoptotic protein Bax in the Bcl-2 family were then studied. Our results showed that Bax was significantly increased and Bcl-2 was significantly decreased in the HG group. BSF decreased Bax expression and increased Bcl-2 expression induced by HG in an in vitro study (Figures 6(f)–6(h)). Accordingly, HG-induced high caspase-3 activity was lowered by BSF treatment (Figure 6(i)). More importantly, we also found that the antiapoptotic effect of BSF was p38 pathway-dependent, since p38 pathway inhibitor SB203580 could suppress the podocyte apoptosis induced by HG (Figure 6(k)).

**3.8. p38 Phosphorylation Induced Podocyte Apoptosis Was NOX-4-Dependent.** To demonstrate the relationship between p38 phosphorylation and NOX-4 activation, the p38 pathway was studied after the podocytes were transfected with NOX-4 siRNA. In our study, NOX-4 silence significantly inhibited p38 phosphorylation induced by HG in cultured podocytes (Figures 7(a)–7(c)). Moreover, the high caspase-3 activity was significantly decreased by NOX-4 siRNA in HG-cultured podocytes (Figure 7(d)). It indicates that the antiapoptotic effect of BSF is NOX-4/p38 pathway-dependent.

**4. Discussion**

Diabetic nephropathy, as the most common microvascular complication of diabetic mellitus, has been the leading cause of end-stage renal disease [2]. Data from clinical trials indicates that 40% of end-stage renal disease patients and 50% of dialysis and kidney transplant patients are induced by DN [10]. However, the pathomechanism of DN has been unclear. Meanwhile, the effective clinical intervention is limited for DN patients. Thus, it is important for us to seek a potential therapeutic target of DN. As we know, microalbuminuria is the typical clinical symptom of the early stage of DN [11]. Microalbuminuria is also the key cause which can lead to rapid progression of DN [1]. Moreover, reducing urinary protein excretion has been the important therapeutic method in recent years. BSF, a kind of traditional Chinese medicine compound, has been widely used in treatment of DN in our clinical practice. BSF can significantly decrease proteinuria and serum creatinine of DN patients, although it has no obvious influence on eGFR (data was not shown). In our in vivo study, we found that BSF significantly decreased urinary albumin excretion of diabetic rats. Moreover, in the main substances of BSF, it has been demonstrated that quercetin [12], salvianolic acid B [13], and luteolin [14] can decrease oxidative stress in many diseases. Moreover, astragaloside IV could protect podocytes from injury via inhibiting oxidative stress, as demonstrated in a previous study [15]. It indicates that BSF probably prevents the progression of DN by offering antioxidative activity.
Figure 6: Continued.
Podocyte, as an important component of glomerular filtration membrane, has been the research focus and important potential therapeutic target of DN in recent years [16–18]. Meanwhile, podocyte injury plays a key role in increased urinary albumin in DN [19–22]. Nephrin, a signature molecule of podocyte, can regulate many pivotal functions of podocyte [5]. Research suggests that nephrin expression is important for signal transduction and cytoskeletal reorganization of podocyte. Moreover, podocyte is a kind of terminal differentiation cell and has lost the ability for regenerative repairation. A decrease in the number of podocytes can lead to destruction of GBM and increased urinary albumin [23–25]. The previous study has demonstrated that podocyte apoptosis is the leading cause of the decrease in the number of podocytes in DN [19, 20]. Thus, decreased nephrin expression and increased podocyte apoptosis is a good marker of podocyte injury. Evidence suggests that nephrin expression is significantly decreased and podocyte apoptosis is significantly increased in DN. We also explored nephrin expression and podocyte apoptosis in diabetic rats and high glucose cultured podocyte in our study. In accordance with the previous study, nephrin expression is significantly decreased and podocyte apoptosis is significantly increased in DN. More importantly, BSF significantly increased nephrin expression and decreased podocyte apoptosis in diabetic rats and high glucose cultured podocytes. Our results indicate that BSF can protect podocytes from injury in DN.

Oxidative stress has been the central pathomechanism of podocyte injury in DN [7, 26]. ROS production is significantly increased in podocyte in DN, which has been demonstrated by many previous studies. Moreover, there are many ways involved in increased ROS production in podocyte. However, NADPH is the major source of ROS in podocyte in DN. NOX-4, as a member of the NADPH oxidase family, has been the key oxidase in increased ROS production in podocyte in DN [27]. It has been demonstrated that HG can increase NOX-4 expression and ROS production in podocyte, which is the major cause of podocyte apoptosis [7, 27]. Moreover, NOS, T-SOD, and MDA are also good markers of oxidative stress [15]. In order to explore the effect of BSF on podocyte oxidative stress, ROS, NOX-4, NOS, T-SOD, and MDA were detected in our in vivo and in vitro study. Our results showed that BSF significantly inhibited podocyte oxidative stress in DN.

The p38 pathway is an important mechanism of podocyte injury in DN [28]. Some reports suggest that the p38 pathway can be activated by oxidative stress in podocyte [9]. The p38 pathway has an intensive relationship with podocyte apoptosis [8]. The activated p38 pathway can lead to increased Bax expression and decreased Bcl-2 expression [29]. As we know, Bax is a kind of proapoptotic protein and Bcl-2 is a kind of inhibitor of apoptosis protein. Thus, increased podocyte apoptosis can be induced by the activated p38 pathway. Moreover, p38 pathway activation
Figure 7: Effect of NOX-4 siRNA on p38 pathway-induced apoptosis in HG cultured podocytes. (a) Representative band of p38 and P-p38 protein in cultured podocyte. (b, c) Comparison of the grey values of P-p38 and p38 protein in cultured podocyte. NOX-4 siRNA significantly decreased the expression P-p38 protein compared with the HG group. (d) Comparison of caspase-3 activity in cultured podocyte. NOX-4 siRNA significantly decreased the caspase-3 activity in HG cultured podocytes. *P < 0.05 and ***P < 0.001 versus NG. #P < 0.05 and ##P < 0.01 versus HG.
decreases nephrin expression and induces podocyte injury, which has been demonstrated by previous studies. To explore the molecular mechanism of BSF on podocyte injury, p38 pathway, Bax, and Bcl-2 expression were detected in our study. Our results showed that P-p38 protein was significantly increased in podocyte of the HG group. Moreover, Bax protein was significantly increased and Bcl-2 protein was significantly decreased in podocyte of the HG group. More importantly, BSF could significantly decrease p38 phosphorylation after exposure of podocyte to HG. Bax expression was significantly decreased, and Bcl-2 expression was significantly increased in the BSF group compared with the HG group.

In conclusion, BSF could prevent the development of DN. The renoprotection might be attributed to an inhibitive effect of the NOX-4/ROS/p38 pathway in podocytes (Figure 8).

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Conflicts of Interest**

The authors declare that they have no competing interests.

**Authors’ Contributions**

Fang-qiang Cui and Long Tang contributed equally to this work.

**Acknowledgments**

This work was supported by grants from an open research program of the Key Lab of Capital Medical University, the National Natural Science Foundation of China (No. 81703989 and 81774278), and the Provincial Natural Science Foundation of Beijing (No. 7182069 and 7172096).

**References**

[1] J. Ahmad, "Management of diabetic nephropathy: recent progress and future perspective," *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, vol. 9, no. 4, pp. 343–358, 2015.
[2] H. Pavenstadt, W. Kriz, and M. Kretzler, "Cell biology of the glomerular podocyte," *Physiological Reviews*, vol. 83, no. 1, pp. 253–307, 2003.

[3] B. F. Palmer, "Supratherapeutic doses of angiotensin receptor blockers to decrease proteinuria in patients with chronic kidney disease," *American Journal of Nephrology*, vol. 28, no. 3, pp. 381–390, 2008.

[4] F. Cui, D. Zou, Y. Gao et al., "Effect of Tongxinluo on nephron expression via inhibition of Notch1/snail pathway in diabetic rats," *Evidence-based Complementary and Alternative Medicine*, vol. 2015, Article ID 424193, 11 pages, 2015.

[5] G. I. Welsh and M. A. Saleem, "Nephrin—signature molecule of the glomerular podocyte?," *Journal of Pathology*, vol. 220, no. 3, pp. 328–337, 2010.

[6] A. Piekowska, D. Rogacka, I. Audzuyenka, M. Jankowski, and S. Angielks, "High glucose concentration affects the oxidant-antioxidant balance in cultured mouse podocytes," *Journal of Cellular Biochemistry*, vol. 112, no. 6, pp. 1661–1672, 2011.

[7] K. Susztak, A. C. Raff, M. Schiffer, and E. P. Bottinger, "Glucose-secreting reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy," *Diabetes*, vol. 55, no. 1, pp. 225–233, 2006.

[8] M. Koshikawa, M. Mukoyama, K. Mori et al., "Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome," *Journal of the American Society of Nephrology*, vol. 16, no. 9, pp. 2690–2701, 2005.

[9] K. Gao, Y. Chi, W. Sun, M. Takeda, and J. Yao, "5′-AMP-activated protein kinase attenuates adriamycin-induced oxidative podocyte injury through thioredoxin-mediated suppression of the apoptosis signal-regulating kinase 1-P38 signaling pathway," *Molecular Pharmacology*, vol. 85, no. 3, pp. 460–471, 2014.

[10] W. Lv, Y. Zhang, G. Guan, P. Li, J. Wang, and D. Qi, "Myco-phenolate mofetil and valsartan inhibit podocyte apoptosis in streptozotocin-induced diabetic rats," *Pharmacology*, vol. 92, no. 3–4, pp. 227–234, 2013.

[11] B. F. Palmer, "Proteinuria as a therapeutic target in patients with chronic kidney disease," *American Journal of Nephrology*, vol. 27, no. 3, pp. 287–293, 2007.

[12] I. Ben Salem, M. Boussabbeh, I. Graiet, A. Rhouma, H. Bacha, and S. Abid Essef, "Quercetin protects HCT116 cells from Dichlorvos-induced oxidative stress and apoptosis," *Cell Stress & Chaperones*, vol. 21, no. 1, pp. 179–186, 2016.

[13] D.-H. Zhao, Y.-J. Wu, S.-T. Liu, and R.-Y. Liu, "Salvianolic acid B attenuates lipopolysaccharide-induced acute lung injury in rats through inhibition of apoptosis, oxidative stress and inflammation," *Experimental and Therapeutic Medicine*, vol. 14, no. 1, pp. 759–764, 2017.

[14] M. Hytti, N. Pippio, E. Korhonen, P. Honkakoski, K. Kaarniranta, and A. Kauppinen, "Fisetin and luteolin protect human retinal pigment epithelial cells from oxidative stress-induced cell death and regulate inflammation," *Scientific Reports*, vol. 5, no. 1, article 17645, 2015.

[15] D. Gui, Y. Guo, F. Wang et al., "Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo," *PLoS One*, vol. 7, no. 6, article e39824, 2012.

[16] M. W. Steffes, D. Schmidt, R. McCrery, J. M. Basgen, and International Diabetic Nephropathy Study Group, "Glomerular cell number in normal subjects and in type 1 diabetic patients," *Kidney International*, vol. 59, no. 6, pp. 2104–2113, 2001.

[17] M. E. Pagtalunan, P. L. Miller, S. Jumping-Eagle et al., "Podocyte loss and progressive glomerular injury in type II diabetes," *The Journal of Clinical Investigation*, vol. 99, no. 2, pp. 342–348, 1997.

[18] T. W. Meyer, P. H. Bennett, and R. G. Nelson, "Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria," *Diabetologia*, vol. 42, no. 11, pp. 1341–1344, 1999.

[19] J. Xu, Z. Li, P. Xu, and Z. Yang, "Protective effects of leukemia inhibitory factor against oxidative stress during high glucose-induced apoptosis in podocytes," *Cell Stress and Chaperones*, vol. 17, no. 4, pp. 485–493, 2012.

[20] E. Riedl, F. Pfister, M. Braunegel et al., "Carnosine prevents apoptosis of glomerular cells and podocyte loss in STZ diabetic rats," *Cellular Physiology and Biochemistry*, vol. 28, no. 2, pp. 279–288, 2011.

[21] E. Sohn, J. Kim, C.-S. Kim, Y. S. Kim, D. S. Jang, and J. S. Kim, "Extract of the aerial parts of Aster koraiensis reduced development of diabetic nephropathy via anti-apoptosis of podocytes in streptozotocin-induced diabetic rats," *Biochemical and Biophysical Research Communications*, vol. 391, no. 1, pp. 733–738, 2010.

[22] H. Wang, T. Madhusudhan, T. He et al., "Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy," *Blood*, vol. 117, no. 19, pp. 5231–5242, 2011.

[23] C. Li and H. M. Siragy, "High glucose induces podocyte injury via enhanced (Pro)renin receptor-Wnt-β-catenin-snail signaling pathway," *PLoS One*, vol. 9, no. 2, article e89233, 2014.

[24] G. Li, Y. Li, S. Liu et al., "Gremlin aggravates hyperglycemia induced podocyte injury by a TGFβ/smad dependent signaling pathway," *Journal of Cellular Biochemistry*, vol. 114, no. 9, pp. 2101–2113, 2013.

[25] S. Doublier, G. Salviod, E. Lupia et al., "Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II," *Diabetes*, vol. 52, no. 4, pp. 1023–1030, 2003.

[26] A. A. Eid, Y. Gorin, B. M. Fagg et al., "Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases," *Diabetes*, vol. 58, no. 5, pp. 1201–1211, 2009.

[27] J. Toyonaga, K. Tsuruya, H. Ikeda et al., "Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production," *Nephrology Dialysis Transplantation*, vol. 26, no. 8, pp. 2475–2484, 2011.

[28] F. Cui, Y. Gao, W. Zhao et al., "Effect of Tongxinluo on podocyte apoptosis via inhibition of oxidative stress and P38 pathway in diabetic rats," *Evidence-based Complementary and Alternative Medicine*, vol. 2016, Article ID 5957423, 10 pages, 2016.

[29] A. Van Laethem, S. Van Kelst, S. Lippens et al., "Activation of p38 MAPK is required for Bax translocation to mitochondria, cytochrome c release and apoptosis induced by UVB irradiation in human keratinocytes," *The FASEB Journal*, vol. 18, no. 15, pp. 1946–1948, 2004.